How many drugs treat Gastrointestinal stromal tumor?

Drug Landscape tracks 8 marketed treatments for Gastrointestinal stromal tumor (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/gastrointestinal-stromal-tumor.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Gastrointestinal stromal tumor — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gastrointestinal stromal tumor (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Gastrointestinal stromal tumor, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Ayvakit	AVAPRITINIB	Blueprint Medicines	Kinase Inhibitor [EPC]	Platelet-derived growth factor receptor alpha	2020-01-01
Stivarga	regorafenib	Bayer	Kinase Inhibitor	Bifunctional epoxide hydrolase 2	2012-01-01
Sunitinib Malate	sunitinib-malate	Pfizer	Moderate Risk QT Prolonging Agents	3-phosphoinositide-dependent protein kinase 1	2006-01-01
Sutent	Sunitinib Malate	Pfizer	Small molecule kinase inhibitor	Receptor tyrosine kinases (RTKs): PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, RET	2006-01-01
Sutent	sunitinib	Pfizer	Moderate Risk QT Prolonging Agents	3-phosphoinositide-dependent protein kinase 1	2006-01-01
Gleevec	imatinib	Novartis	Kinase Inhibitor	Receptor tyrosine-protein kinase erbB-2	2001-01-01
Jeselhy	Pimitespib	Taiho Pharmaceutical Co., Ltd		Heat shock protein HSP 90-beta
Gleevec	Gleevec	M.D. Anderson Cancer Center		Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 3 drugs in Gastrointestinal stromal tumor
Bayer · 1 drug in Gastrointestinal stromal tumor
Blueprint Medicines · 1 drug in Gastrointestinal stromal tumor
M.D. Anderson Cancer Center · 1 drug in Gastrointestinal stromal tumor
Novartis · 1 drug in Gastrointestinal stromal tumor
Taiho Pharmaceutical Co., Ltd · 1 drug in Gastrointestinal stromal tumor

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Gastrointestinal stromal tumor:

Cite this brief

Drug Landscape (2026). Gastrointestinal stromal tumor — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/gastrointestinal-stromal-tumor. Accessed 2026-06-10.

Gastrointestinal stromal tumor full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing